Endoplasmic reticulum (ER) News and Research

RSS

New study: Minority women may face risk of prenatal depression during pregnancy

A new study finds that African-American and Asian/Pacific Islander women have double the risk that others do of becoming depressed before giving birth, after adjusting for socioeconomic risk factors.

23 Mar 2011

Viewpoints: Houston's 'painful' E.R. decision; Arizona's 'war' on kids' health care; protecting elders from abuse

Women are the majority of public-sector employees at the state and local levels and have already lost 320,000 public-sector jobs in the past two years. In addition, the GOP majority is attempting to defund Title X services, which have connected millions of American women to health care since 1970.

18 Mar 2011

New findings reveal abused women are frequent ER visitors for many health problems

More than three quarters of domestic violence victims who report the incidents to police seek health care in emergency rooms, but most of them are never identified as being victims of abuse during their hospital visit.

17 Mar 2011

Light files contractual lawsuit against Creation in Tel-Aviv District Court

Light Instruments Ltd., a subsidiary company of Syneron Medical Ltd. and a leading manufacturer of the LiteTouch and Laser-in-Handpiece dental laser breakthrough technologies has filed a lawsuit on March 9, 2011, at the Tel-Aviv District Court, against Creation S.r.l., an Italian company, headed by its CEO, Professor Alfred Resch.

16 Mar 2011

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.

16 Mar 2011

Anavex to commence phase I clinical trial in Alzheimer’s disease

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

State roundup: Medicaid cuts cause unusual bedfellows

Representatives from Arizona hospitals, nursing homes and health plans are set to meet with Gov. Jan Brewer today. They hope to win her support for a plan to impose a tax on their institutions and avoid deep cuts to Arizona's Medicaid program. The plan reportedly includes a cap on funding for childless adults, a group now covered under the Arizona Health Care Cost Containment System that could lose coverage Oct. 1. (Reinhart, 3/11).

14 Mar 2011

Pawlenty assails government-run health care in N.H. trip

Likely presidential hopeful Tim Pawlenty urged a roomful of skeptical doctors Friday to be leaders rather than be dragged into what he sees as the future of health care -- giving consumers more information and choices and rewarding providers for quality over volume.

14 Mar 2011

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events as outlined in the recently updated NCCN Guidelines™ for Breast Cancer. Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Breast Cancer, presented these and other notable updates to the NCCN Guidelines at the NCCN 16th Annual Conference on March 10, 2011.

11 Mar 2011

FDA approves Amneal's Indomethacin ER capsules

Amneal Pharmaceuticals, LLC is pleased to announce that it received U.S. FDA approval for Indomethacin Extended Release capsules, USP in the 75 mg strength effective December 1, 2010.

3 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon but particularly aggressive subtype of the disease.

24 Feb 2011

Longer looks: KHN's best health policy picks from thought-provoking publications

A law under consideration in South Dakota would expand the definition of "justifiable homicide" to include killings that are intended to prevent harm to a fetus—a move that could make it legal to kill doctors who perform abortions.

18 Feb 2011

PM Pediatrics launches new location in Bayside, Queens

PM Pediatrics, the preeminent provider of after-hours pediatric urgent care in New York, operating urgent care practices in Nassau, Suffolk and Westchester counties, today announced the launch of its newest location in Bayside, Queens. Beginning Friday, March 11, 2011, the urgent care site, located at 210-31 26th Avenue in the popular Bay Terrace Shopping Center, will open its doors to the community.

17 Feb 2011

Genetic proof for anti-cancer properties of antioxidants and autophagy inhibitors

Researchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress-a culprit in driving tumor growth.

16 Feb 2011